The company is running out of chances for its inhaled interferon therapy after a Phase III study failed to show benefits for hospitalized COVID-19 patients.
The chances of Synairgen bringing its inhaled COVID-19 candidate to market have dwindled after a failure in a hospital-based Phase III trial.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
